Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07241260

Hydrate Heroes for Improving Brain Function & Mood

Boosting Brain and Mood: Exploring the Impact of Hydrate Heroes on Mental Health and Brain Activity

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
University of South Florida · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The primary goal of this 12-week randomized controlled study is to evaluate whether daily use of Hydrate Heroes results in measurable improvements in brain activity, mental health, and performance on cognitive tasks. By analyzing brainwave data, physical response metrics, and patient-reported outcomes, the study will demonstrate whether the supplement produces meaningful effects on mental and neurological health.

Detailed description

The study will utilize electrophysiological measurements of the brain and body. EEG recordings will be captured using the Emotiv FLEX 2.0 wireless headset, which measures brainwave activity across 32 electrode sites using a standard 10-10 system. EEG data will be collected at 256 Hz and analyzed using EEGLAB software to assess spectral power and topographic changes over time. The protocol includes 20 minutes of EEG testing per session, with specific tasks designed to elicit measurable cognitive responses. Participants will wear an Empatica Embrace wristband during testing to collect physiological data including motion, stress indicators, and heart rate variability. Participants will complete a series of validated tests on an iPad while wearing the EEG headset and wrist device. Tasks include: * Grandfather Passage (speech task) * Card Matching (memory and attention) * Boston Naming Test (language) * Finger Tapping (motor speed) * Trail Making Test (executive function) * Dual-Task Performance (cognitive load) Over 500 digital data features will be captured per session using a system that combines inputs from device sensors (e.g., gyroscope, camera, microphone) with user interactions (e.g., tapping, speech, app use). Participants will complete standardized questionnaires, including PROMIS-29+2 and IPAQ-SF, to assess aspects such as emotional well-being, physical activity, fatigue, and pain. The PROMIS-29+2 is aA collection of short forms or computer adaptive tests containing a fixed number of items from seven PROMIS domains (Depression, Anxiety, Physical Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities) The PROMIS-29+2 is used to calculate a preference score. Preference-based scores provide an overall summary of health-related quality of life on a common metric. Preference-based scores summarize multiple domains on a metric ranging from 0 (as bad as dead) to 1 (perfect or ideal health). Scores can be used in comparisons across groups and for cost-utility analyses. The profile includes all items in the PROMIS-29 Profile v2.1 plus two Cognitive Function Abilities items. T-scores from the measure can be used to calculate a preference-based score. International Physical Activity Questionnaire (IPAQ) short form is an 8-item questionnaire that encompasses time spent walking, in moderate and vigorous physical activity. The short form is feasible to administer and shows similar reliability and validity results in comparison to the long form. Test-rest reliability indicates good stability and high reliability (α \<.80). Scoring provides a categorization of low, moderate, or high intensity of physical activity. Ideally, this will be performed pre- and post-intervention.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTHydrate Heroes (6 packets)Participants that are randomized to the active comparator groups will receive 6 packets of Hydrate Heroes to use daily.
DIETARY_SUPPLEMENTHydrate Heroes (3 packets)Participants that are randomized to the active comparator groups will receive 3 packets of Hydrate Heroes to use daily.

Timeline

Start date
2025-12-01
Primary completion
2026-11-30
Completion
2026-12-31
First posted
2025-11-21
Last updated
2025-11-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07241260. Inclusion in this directory is not an endorsement.